Dr Sarah Hernandez
Editor
Massachusetts, USA
Dr. Sarah Hernandez is the Director of Research Programs at the Hereditary Disease Foundation (HDF). She carried out her postdoctoral work with Dr. Leslie Thompson at the University of California, Irvine, where she used stem cells and fruit flies to define HD-related changes that exist outside the cell, in the “extracellular matrix”. At the HDF, Sarah oversees the Foundation’s scientific research portfolio by managing the grants program, acting as the scientific liaison, and coordinating scientific programming through webinars, workshops, and conferences. Sarah enthusiastically supports the mission of the HDF, to identify the most promising research and accelerate treatments for Huntington’s disease.
Articles edited by Dr Sarah Hernandez
- Huntington’s disease therapeutics conference 2023 - Day 3
- Huntington’s disease therapeutics conference 2023 - Day 2
- Huntington’s disease therapeutics conference 2023 - Day 1
- Hereditary Disease Foundation (HDF) conference 2022 – Day 4
- Hereditary Disease Foundation (HDF) conference 2022 – Day 3
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
- Huntington’s disease therapeutics conference 2022 - Day 2
- Huntington’s disease therapeutics conference 2022 - Day 1
- Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing
- Sad news from the SIGNAL study: pepinemab does not influence HD symptoms
- HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
Articles written by Dr Sarah Hernandez
- Start here!
- Astrocytes: The new star in HD research?
- Hunting for balance: how the huntingtin protein compensates in HD
- Hereditary Disease Foundation (HDF) conference 2022 – Day 4
- Hereditary Disease Foundation (HDF) conference 2022 – Day 3
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Huntington’s disease therapeutics conference 2022 - Day 2
- Huntington’s disease therapeutics conference 2022 - Day 1
- A new roadmap to track Huntington’s disease progression
- Huntington’s disease therapeutics conference 2022 - Day 3
- Oral drug may change the story for huntingtin lowering
- Real talk: Q&A with Roche about GENERATION-HD1
- Unpacking recent gene therapy press
- Working as a team: Changes in brain development mean some brain regions may be slacking off
- Changing jobs: converting other cell types into neurons
- HD Young Adult Study defines the sweet spot: symptom-free with measurable changes
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
- What does COVID-19 mean for Huntington’s disease families and HD research?
- Huntington’s disease therapeutics conference 2020 - Day 1
- Huntington’s disease therapeutics conference 2020 - Day 3
- Huntington’s disease therapeutics conference 2020 - Day 2
- The third dimension: using minibrains to understand brain development changes in HD